BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15064693)

  • 1. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
    Buser AS; Heim D; Bucher C; Tichelli A; Gratwohl A; Passweg JR
    Bone Marrow Transplant; 2004 May; 33(10):1011-4. PubMed ID: 15064693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
    Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
    J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D
    Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic transplantation in malignant lymphoma].
    Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
    J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect.
    Glass B; Nickelsen M; Dreger P; Claviez A; Hasenkamp J; Wulf G; Trümper L; Schmitz N
    Bone Marrow Transplant; 2004 Sep; 34(5):391-7. PubMed ID: 15273707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma.
    Tanimoto TE; Kusumi E; Hamaki T; Yuji K; Ueyama J; Miyakoshi S; Morinaga S; Kami M; Kanda Y; Ando T; Yoshihara S; Masuo S; Kim SW; Nakai K; Tobinai K; Tanosaki R; Mineishi S; Takaue Y; Muto Y
    Bone Marrow Transplant; 2003 Jul; 32(2):131-7. PubMed ID: 12838276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.